Funding for this research was provided by:
University of Gothenburg
Received: 25 August 2021
Accepted: 13 December 2021
First Online: 22 December 2021
: This study was approved by the Human Research Ethics Committee of the Medical Faculty, University of Gothenburg, (Sweden) (Dnr: Ö588–01). All patient information was confidentially treated. Anonymous, coded identification was used. Written informed consent was obtained from all participants or, if their capacity to provide consent was questioned, consent was also obtained from those with power of attorney.
: Not applicable.
: Birgitta Anesten reports no disclosures.Henrik Zetterberg reports that he has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).Staffan Nilsson reports no disclosures.Bruce Brew reports no disclosures.Dietmar Fuchs reports no disclosures.Richard W Price reports no disclosures.Magnus Gisslén reports no disclosures.Aylin Yilmaz reports no disclosures.